TSE:MDNA Medicenna Therapeutics (MDNA) Stock Price, News & Analysis C$1.08 0.00 (0.00%) As of 08/15/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock About Medicenna Therapeutics Stock (TSE:MDNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Medicenna Therapeutics alerts:Sign Up Key Stats Today's RangeC$1.04▼C$1.1050-Day RangeC$0.80▼C$1.1952-Week RangeC$0.78▼C$2.63Volume37,403 shsAverage Volume46,357 shsMarket CapitalizationC$80.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients. Read More Receive MDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MDNA Stock News HeadlinesMedicenna Therapeutics Corp.: Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational HighlightsJune 26, 2025 | finanznachrichten.deMedicenna to Present at Jones Healthcare and Technology Innovation ConferenceApril 1, 2025 | markets.businessinsider.comGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly income to cover housing, healthcare, food, and fun... With a fraction of what you probably think you need. | Investors Alley (Ad)Medicenna Therapeutics reports clinical data from ABILITY-1 study of MDNA11February 25, 2025 | markets.businessinsider.comMedicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated MilestonesFebruary 13, 2025 | uk.finance.yahoo.comMedicenna’s MDNA11 Shows Promising Cancer Treatment ResultsDecember 6, 2024 | markets.businessinsider.comMedicenna Therapeutics Corp.: Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate UpdateNovember 15, 2024 | finanznachrichten.deMedicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate UpdateNovember 15, 2024 | finance.yahoo.comSee More Headlines MDNA Stock Analysis - Frequently Asked Questions How have MDNA shares performed this year? Medicenna Therapeutics' stock was trading at C$1.65 at the beginning of 2025. Since then, MDNA shares have decreased by 34.5% and is now trading at C$1.08. How do I buy shares of Medicenna Therapeutics? Shares of MDNA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Medicenna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medicenna Therapeutics investors own include Manulife Financial (MFC), Gilead Sciences (GILD), OPKO Health (OPK), Air Canada (AC), Athersys (ATHX), Birchcliff Energy (BIR) and Canadian Natural Resources (CNQ). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolTSE:MDNA CIKN/A Webwww.medicenna.com Phone+1-403-6807898FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$25.98 million Net Margins-533,640.00% Pretax MarginN/A Return on Equity-159.88% Return on Assets-32.80% Debt Debt-to-Equity Ratio0.88 Current Ratio11.40 Quick Ratio4.65 Sales & Book Value Annual SalesC$4.87 thousand Price / Sales16,596.92 Cash FlowC$0.94 per share Price / Cash Flow1.15 Book ValueC$0.26 per share Price / Book4.14Miscellaneous Outstanding Shares74,815,113Free FloatN/AMarket CapC$80.80 million OptionableNot Optionable Beta1.21 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (TSE:MDNA) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredAmerica’s Finest Hour: Sept 30After This White House Deadline, All Bets Are Off The White House just issued a sweeping order that could s...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicenna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.